MEDICURE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.09 CAD | +10.10% |
|
+0.93% | -22.14% |
| Apr. 09 | Transcript : Medicure Inc., 2023 Earnings Call, Apr 09, 2024 | |
| Apr. 08 | Medicure Swung to a Loss in 2023 on Lower Sales | MT |
| Sales 2022 | 23.06M 16.84M | Sales 2023 | 21.69M 15.83M | Capitalization | 14.61M 10.66M |
|---|---|---|---|---|---|
| Net income 2022 | 1M 730K | Net income 2023 | - 0 | EV / Sales 2022 | 0.28 x |
| Net cash position 2022 | 4.01M 2.93M | Net cash position 2023 | 5.82M 4.25M | EV / Sales 2023 | 0.4 x |
| P/E ratio 2022 |
7.71
x | P/E ratio 2023 |
-15.6
x | Employees | 38 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.01% |
More Fundamentals
* Assessed data
More news
Latest transcript on Medicure Inc.
More press releases
| 1 day | +10.10% | ||
| 1 week | +0.93% | ||
| Current month | -5.22% | ||
| 1 month | -5.22% | ||
| 3 months | -5.22% | ||
| 6 months | -39.44% | ||
| Current year | -22.14% |
1 week
0.99
1.09
1 month
0.991.20
Current year
0.991.45
1 year
0.991.80
3 years
0.801.80
5 years
0.006.35
10 years
0.0010.67
| Managers | Title | Age | Since |
|---|---|---|---|
Albert Friesen
CEO | Chief Executive Officer | 76 | 97-09-14 |
Haaris Uddin
DFI | Director of Finance/CFO | - | 22-05-31 |
Neil Owens
PSD | President | - | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Arnold Naimark
BRD | Director/Board Member | 90 | 00-02-27 |
Peter Quick
BRD | Director/Board Member | 68 | 05-11-28 |
Albert Friesen
CEO | Chief Executive Officer | 76 | 97-09-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1.09 | +10.10% | 3,000 |
| 24-04-22 | 0.99 | -3.88% | 3,300 |
| 24-04-18 | 1.03 | -4.63% | 16,930 |
| 24-04-17 | 1.08 | 0.00% | 260 |
| 24-04-16 | 1.08 | +1.89% | 100 |
Delayed Quote Toronto S.E., April 24, 2024 at 03:29 pm EDT
More quotes
Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Companyâs United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Calendar
2024-05-26
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -22.14% | 7.56M | |
| -1.51% | 105B | |
| +3.22% | 97.5B | |
| +1.86% | 22.19B | |
| -16.53% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.09% | 14.52B | |
| +5.47% | 14.09B | |
| +28.85% | 10.99B |
- Stock Market
- Equities
- MPH Stock
